European Archives - Page 866 of 1108 - European Medical Journal

Innovation That Drives Your Dermatological Future

This symposium is focused on topical therapies in the treatment of psoriasis and the unmet clinical and patient quality of life needs.

The Impact of Air Pollution on Skin and Related Protection By Thermal Spring Water

In epidemiological studies, it has been shown that exposure to airborne, traffic-related particulate matter (PM) is associated with increased skin…

Advancing Science: Driving Progress Today for a Clearer Tomorrow

Dermatologists today have more tools than ever at their disposal for managing psoriasis, including newer-generation biologics, which target molecular…

Special Poster Feature: Certolizumab Pegol: A Future Treatment Option for Patients Suffering from Psoriasis

Psoriasis is a chronic inflammatory disease that is associated with a reduction in quality of life (QoL) and professional work productivity.

Is The Anti-NXP-2 (Anti-MJ) Antibody a Marker Antibody for Dysphagia in Dermatomyositis? A Report of Three Cases

Dermatomyositis (DM) is an autoimmune myopathy of unknown aetiology and involves the development of characteristic skin manifestations, muscle weakness…

Editor’s Pick: Hidradenitis Suppurativa (Acne Inversa): A Review of Aetiopathogenesis and Management

Hidradenitis suppurativa is a debilitating, chronic, relapsing inflammatory condition associated with the development of painful nodules.

Case Series of Vasculitides: An On-Call Experience

The EADV annual congress is one of the most prestigious and well-attended dermatology conferences in the world.

Successful Treatment of Epidermolysis Bullosa Acquisita with Rituximab–Intravenous Immunoglobulin Combination

Epidermolysis bullosa acquisita (EBA) is a rare, sub-epithelial, mechano-bullous blistering disease that usually develops in adulthood.

Chronic Urticaria in Children: A Review

In children, chronic urticaria is substantially less common than acute urticaria but is associated with a larger decrease in quality of life. Read to find out more.

Cost-Effective Therapeutic Modalities in Alopecia Areata

The patches of hair loss in alopecia areata occur as a result of T cell mediated loss of immune privilege.